Not registered yet? Please contact our project manager Vanessa Köhler.

2 November 2023

TIMESPAN at ODISSEI conference 2023

Last week, Catharina Hartman of Partner UMCG presented during the ODISSEI conference: “The association between Attention Deficit Hyperactivity Disorder and treatment discontinuation ...
Read article …
9 November 2023

TIMESPAN 6th SC meeting

Our 6th Steering Committee meeting will be held remotely on November 9th, 2023. During this full-day meeting, we look forward to hearing about the work packages' progress, productive discus...
Read more …
30 November 2023

Masterclass #3: ADHD Biomarkers by Prof. Dr. Jan Buitelaar

Prof. Dr. Jan Buitelaar, professor of child and adolescent psychiatry at Radboud University Medical Center, provides a thorough overview of current research on ADHD biomarkers in this maste...
Read more …


Emerging evidence points at a significant association and shared genetic traits between adult attention-deficit / hyperactivity disorder (ADHD) and cardiometabolic conditions such as obesity, type 2 diabetes, and cardiovascular disease, which, when inadequately treated, can lead to adverse outcomes and significant costs for society. Various national guidelines on cardiometabolic disease already highlight the importance of concurrent psychiatric disorders, but there is a lack of knowledge around ADHD. This is problematic given that ADHD is a common, serious, and complex chronic condition among adults. This is where TIMESPAN steps in, fostering improvements in risk stratification and of the treatments for patients with ADHD who also have a cardiometabolic disease.

Read more


  • Determine if and how ADHD in adults worsens prognosis and hampers the management of cardiometabolic disease, leveraging the largest data sets and population registries available world-wide.
  • Identify the cardiometabolic risks and benefits of multidisciplinary treatment approaches in patients with ADHD, performing advanced pharmacological and epidemiological analyses on available data as well as  acquiring new and unique real-world data using active and passive apps for smartphones and a groundbreaking new advanced smartwatch for continuous health monitoring.
  • Pinpoint reasons for ADHD treatment discontinuity in adult patients with and without cardiometabolic disease. Capitalizing on so far unused real-world clinician’s data through new algorithms, created utilizing Machine Learning (ML) and natural language processing techniques in conjunction with using state-of-the-art genomic approaches.
  • Discern patients with ADHD at high-risk for poor cardiometabolic outcomes and treatment discontinuity by applying novel AI driven methods like deep learning neural networks (DLNNs) on existing large-scale cohort  studies and linked electronic health record databases in multiple countries with different health care systems.
  • Identify optimized and personalized treatment approaches across multiple disciplines, to minimize harm and maximize positive changes in disease prognosis and to improve treatment discontinuity.
  • Improve clinical outcomes, as well as quality of life in adult ADHD patients with co-occurring cardiometabolic disease.